
SMS Lifesciences (SMSLIFE) | Financial Analysis & Statements
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Mar 2025Income Metrics
Revenue
891.1M
Gross Profit
328.0M
36.80%
Operating Income
36.2M
4.07%
Net Income
34.8M
3.91%
Balance Sheet Metrics
Total Assets
3.9B
Total Liabilities
1.8B
Shareholders Equity
2.1B
Debt to Equity
0.84
Cash Flow Metrics
Revenue & Profitability Trend
SMS Lifesciences Income Statement From 2021 to 2025
Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|---|
Revenue | 3.4B | 3.0B | 3.1B | 3.5B | 2.6B |
Cost of Goods Sold | 2.2B | 2.1B | 2.3B | 2.6B | 1.9B |
Gross Profit | 1.3B | 907.7M | 845.5M | 875.4M | 702.1M |
Gross Margin % | 36.3% | 30.3% | 27.1% | 25.2% | 27.3% |
Operating Expenses | |||||
Research & Development | - | - | - | - | - |
Selling, General & Administrative | - | 57.9M | 54.5M | 50.3M | 52.1M |
Other Operating Expenses | 205.4M | 77.9M | 67.6M | 77.9M | 97.6M |
Total Operating Expenses | 205.4M | 135.8M | 122.1M | 128.1M | 149.8M |
Operating Income | 300.4M | 162.8M | 180.5M | 246.5M | 223.9M |
Operating Margin % | 8.7% | 5.4% | 5.8% | 7.1% | 8.7% |
Non-Operating Items | |||||
Interest Income | - | 2.8M | 4.0M | 3.2M | 4.3M |
Interest Expense | 87.1M | 99.5M | 64.2M | 57.0M | 41.6M |
Other Non-Operating Income | - | - | - | - | - |
Pre-tax Income | 261.9M | 98.5M | 165.9M | 327.3M | 195.7M |
Income Tax | 74.6M | 35.2M | 52.2M | 74.3M | 60.1M |
Effective Tax Rate % | 28.5% | 35.7% | 31.4% | 22.7% | 30.7% |
Net Income | 187.3M | 63.3M | 113.8M | 253.0M | 135.6M |
Net Margin % | 5.4% | 2.1% | 3.6% | 7.3% | 5.3% |
Key Metrics | |||||
EBITDA | 499.0M | 347.4M | 314.6M | 356.6M | 315.7M |
EPS (Basic) | ₹66.51 | ₹30.08 | ₹37.92 | ₹83.76 | ₹44.84 |
EPS (Diluted) | ₹66.51 | ₹30.08 | ₹37.92 | ₹83.76 | ₹44.84 |
Basic Shares Outstanding | 3023455 | 3023287 | 3023287 | 3023287 | 3023287 |
Diluted Shares Outstanding | 3023455 | 3023287 | 3023287 | 3023287 | 3023287 |
Income Statement Trend
SMS Lifesciences Balance Sheet From 2021 to 2025
Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|---|
Assets | |||||
Current Assets | |||||
Cash & Equivalents | 5.0M | 5.7M | 12.8M | 9.9M | 85.4M |
Short-term Investments | 10.1M | 9.2M | 23.3M | 23.7M | 20.9M |
Accounts Receivable | 687.9M | 513.5M | 460.6M | 338.3M | 341.5M |
Inventory | 674.0M | 812.1M | 862.3M | 848.1M | 616.3M |
Other Current Assets | 126.5M | 211.7M | 403.1M | -1.0K | 194.4M |
Total Current Assets | 1.5B | 1.6B | 1.6B | 1.6B | 1.3B |
Non-Current Assets | |||||
Property, Plant & Equipment | 2.3B | 42.3M | 34.5M | 38.1M | 25.9M |
Goodwill | 515.0K | 495.0K | 754.0K | 1.1M | 340.4M |
Intangible Assets | - | 495.0K | 754.0K | 1.1M | 1.4M |
Long-term Investments | - | - | - | - | - |
Other Non-Current Assets | 38.8M | 27.3M | -18.0K | 47.7M | -2.0K |
Total Non-Current Assets | 2.4B | 2.4B | 2.4B | 2.0B | 1.8B |
Total Assets | 3.9B | 3.9B | 3.9B | 3.6B | 3.0B |
Liabilities | |||||
Current Liabilities | |||||
Accounts Payable | 532.7M | 591.3M | 596.7M | 778.9M | 611.4M |
Short-term Debt | 664.0M | 651.8M | 442.4M | 374.1M | 255.4M |
Current Portion of Long-term Debt | - | - | - | - | - |
Other Current Liabilities | 77.7M | 98.6M | 40.0K | 56.5M | 167.5M |
Total Current Liabilities | 1.4B | 1.4B | 1.3B | 1.4B | 1.1B |
Non-Current Liabilities | |||||
Long-term Debt | 200.1M | 355.4M | 562.5M | 421.9M | 391.4M |
Deferred Tax Liabilities | 107.4M | 120.4M | 127.6M | 106.8M | 108.3M |
Other Non-Current Liabilities | -1.0K | - | -1.0K | - | 60.0M |
Total Non-Current Liabilities | 358.8M | 523.2M | 731.1M | 563.8M | 590.0M |
Total Liabilities | 1.8B | 2.0B | 2.1B | 1.9B | 1.7B |
Equity | |||||
Common Stock | 30.2M | 30.2M | 30.2M | 30.2M | 30.2M |
Retained Earnings | - | 954.1M | 892.1M | 788.8M | 600.2M |
Treasury Stock | - | - | - | - | - |
Other Equity | - | - | - | - | - |
Total Shareholders Equity | 2.1B | 1.9B | 1.9B | 1.6B | 1.3B |
Key Metrics | |||||
Total Debt | 864.1M | 1.0B | 1.0B | 796.0M | 646.9M |
Working Capital | 85.1M | 107.1M | 255.5M | 205.8M | 122.1M |
Balance Sheet Composition
SMS Lifesciences Cash Flow Statement From 2021 to 2025
Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|---|
Operating Activities | |||||
Net Income | 261.9M | 98.5M | 142.4M | 200.4M | 195.7M |
Depreciation & Amortization | - | - | - | - | - |
Stock-Based Compensation | - | - | - | - | - |
Working Capital Changes | -13.8M | -35.2M | 72.5M | -554.3M | -68.5M |
Operating Cash Flow | 289.7M | 124.7M | 251.1M | -320.5M | 151.3M |
Investing Activities | |||||
Capital Expenditures | -149.8M | -207.4M | -428.0M | -415.2M | -354.7M |
Acquisitions | - | - | - | - | - |
Investment Purchases | - | - | -1.2M | 0 | -20.2M |
Investment Sales | 0 | 23.3M | 112.0M | 337.9M | 38.1M |
Investing Cash Flow | -150.6M | -185.3M | -314.9M | -73.5M | -266.2M |
Financing Activities | |||||
Share Repurchases | - | - | - | - | - |
Dividends Paid | -4.5M | -4.5M | -4.5M | - | - |
Debt Issuance | 3.5M | 0 | 298.1M | 116.9M | 67.8M |
Debt Repayment | -178.0M | -176.2M | -114.4M | -73.1M | -62.7M |
Financing Cash Flow | -142.0M | -14.3M | 208.9M | 130.4M | -2.5M |
Free Cash Flow | 187.1M | 34.4M | -338.6M | -623.9M | -3.9M |
Net Change in Cash | -2.8M | -74.9M | 145.1M | -263.6M | -117.4M |
Cash Flow Trend
SMS Lifesciences Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
16.23
Price to Book
1.66
Price to Sales
0.98
Profitability Ratios
Profit Margin
5.17%
Operating Margin
9.56%
Return on Equity
9.48%
Return on Assets
5.16%
Financial Health
Current Ratio
1.06
Debt to Equity
40.75
Beta
0.26
Per Share Data
EPS (TTM)
₹66.52
Book Value per Share
₹649.96
Revenue per Share
₹1,106.94
Peer Financial Comparison
Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
---|---|---|---|---|---|---|
smslife | 3.3B | 16.23 | 1.66 | 9.48% | 5.17% | 40.75 |
Biocon | 479.6B | 112.27 | 1.99 | 3.66% | 2.44% | 66.26 |
OneSource Specialty | 215.4B | -1,151.60 | 3.65 | -0.31% | -0.85% | 16.03 |
Dishman Carbogen | 42.0B | 1,274.29 | 0.72 | 0.06% | 3.60% | 40.97 |
Zota Health Care | 35.4B | -66.66 | 22.82 | -24.83% | -20.55% | 65.72 |
Panacea Biotec | 25.8B | 91.93 | 3.07 | -1.05% | -1.50% | 2.67 |
Financial data is updated regularly. All figures are in the company's reporting currency.